Imprimis Pharmaceuticals Inc (IMMY) - Financial and Strategic SWOT Analysis Review
![](/report_cover/1896/imprimis-pharmaceuticals-inc-immy-financial-n-strategic-swot-analysis-review_en.gif)
Imprimis Pharmaceuticals Inc (IMMY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Imprimis Pharmaceuticals Inc (Imprimis), formerly Transdel Pharmaceuticals Inc., focuses on the development and commercialization of proprietary drug formulations in the therapeutic areas of urology and ophthalmology. The company by utilizing its SSP Technology develops injectable Dropless Therapy formulations and topical LessDrops formulations. Its Dropless Therapy formulations include injectable Tri-Moxi and Tri-Moxi-Vanc formulations that eliminate the need for eye drops following ocular surgery; and LessDrops include topical eye drop formulations Pred-Moxi and Tri-Moxi for patients following LASIK, cataract, and other ocular surgeries. Imprimis also commercializes heparin and alkalinized lidocaine (Hep-Lido-A or HLA) formulations for the treatment of interstitial cystitis; and injectable pentoxifylline formulation for the treatment of peyronie’s disease. The company markets its products through distributors and compounding pharmacies. Imprimis is headquartered in San Diego, California, the US.
Imprimis Pharmaceuticals Inc Key Recent Developments
May 15,2018: Surface Pharmaceuticals Announces $20 Million Series A Financing from Flying L Partners
May 15,2018: Imprimis Pharmaceuticals Announces First Quarter 2018 Results
Apr 10,2018: Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting
Mar 27,2018: Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation
Mar 08,2018: Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Imprimis Pharmaceuticals Inc (Imprimis), formerly Transdel Pharmaceuticals Inc., focuses on the development and commercialization of proprietary drug formulations in the therapeutic areas of urology and ophthalmology. The company by utilizing its SSP Technology develops injectable Dropless Therapy formulations and topical LessDrops formulations. Its Dropless Therapy formulations include injectable Tri-Moxi and Tri-Moxi-Vanc formulations that eliminate the need for eye drops following ocular surgery; and LessDrops include topical eye drop formulations Pred-Moxi and Tri-Moxi for patients following LASIK, cataract, and other ocular surgeries. Imprimis also commercializes heparin and alkalinized lidocaine (Hep-Lido-A or HLA) formulations for the treatment of interstitial cystitis; and injectable pentoxifylline formulation for the treatment of peyronie’s disease. The company markets its products through distributors and compounding pharmacies. Imprimis is headquartered in San Diego, California, the US.
Imprimis Pharmaceuticals Inc Key Recent Developments
May 15,2018: Surface Pharmaceuticals Announces $20 Million Series A Financing from Flying L Partners
May 15,2018: Imprimis Pharmaceuticals Announces First Quarter 2018 Results
Apr 10,2018: Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting
Mar 27,2018: Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation
Mar 08,2018: Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Imprimis Pharmaceuticals Inc - Key Facts
Imprimis Pharmaceuticals Inc - Key Employees
Imprimis Pharmaceuticals Inc - Key Employee Biographies
Imprimis Pharmaceuticals Inc - Major Products and Services
Imprimis Pharmaceuticals Inc - History
Imprimis Pharmaceuticals Inc - Company Statement
Imprimis Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Imprimis Pharmaceuticals Inc - Business Description
Imprimis Pharmaceuticals Inc - Corporate Strategy
Imprimis Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Imprimis Pharmaceuticals Inc - Strengths
Imprimis Pharmaceuticals Inc - Weaknesses
Imprimis Pharmaceuticals Inc - Opportunities
Imprimis Pharmaceuticals Inc - Threats
Imprimis Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Imprimis Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
May 15, 2018: Surface Pharmaceuticals Announces $20 Million Series A Financing from Flying L Partners
May 15, 2018: Imprimis Pharmaceuticals Announces First Quarter 2018 Results
Apr 10, 2018: Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting
Mar 27, 2018: Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation
Mar 08, 2018: Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results
Mar 06, 2018: Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations
Nov 14, 2017: Imprimis Pharmaceuticals Announces Third Quarter 2017 Results
Oct 24, 2017: Imprimis Launches Surface Pharmaceuticals Subsidiary
Oct 19, 2017: Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis
Oct 02, 2017: Imprimis Pharmaceuticals Secures First Key Composition Patent for Dropless Therapy Formulations
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Imprimis Pharmaceuticals Inc - Key Facts
Imprimis Pharmaceuticals Inc - Key Employees
Imprimis Pharmaceuticals Inc - Key Employee Biographies
Imprimis Pharmaceuticals Inc - Major Products and Services
Imprimis Pharmaceuticals Inc - History
Imprimis Pharmaceuticals Inc - Company Statement
Imprimis Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Imprimis Pharmaceuticals Inc - Business Description
Imprimis Pharmaceuticals Inc - Corporate Strategy
Imprimis Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Imprimis Pharmaceuticals Inc - Strengths
Imprimis Pharmaceuticals Inc - Weaknesses
Imprimis Pharmaceuticals Inc - Opportunities
Imprimis Pharmaceuticals Inc - Threats
Imprimis Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Imprimis Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
May 15, 2018: Surface Pharmaceuticals Announces $20 Million Series A Financing from Flying L Partners
May 15, 2018: Imprimis Pharmaceuticals Announces First Quarter 2018 Results
Apr 10, 2018: Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting
Mar 27, 2018: Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation
Mar 08, 2018: Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results
Mar 06, 2018: Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations
Nov 14, 2017: Imprimis Pharmaceuticals Announces Third Quarter 2017 Results
Oct 24, 2017: Imprimis Launches Surface Pharmaceuticals Subsidiary
Oct 19, 2017: Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis
Oct 02, 2017: Imprimis Pharmaceuticals Secures First Key Composition Patent for Dropless Therapy Formulations
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Imprimis Pharmaceuticals Inc, Key Facts
Imprimis Pharmaceuticals Inc, Key Employees
Imprimis Pharmaceuticals Inc, Key Employee Biographies
Imprimis Pharmaceuticals Inc, Major Products and Services
Imprimis Pharmaceuticals Inc, History
Imprimis Pharmaceuticals Inc, Subsidiaries
Imprimis Pharmaceuticals Inc, Key Competitors
Imprimis Pharmaceuticals Inc, Ratios based on current share price
Imprimis Pharmaceuticals Inc, Annual Ratios
Imprimis Pharmaceuticals Inc, Annual Ratios (Cont.1)
Imprimis Pharmaceuticals Inc, Interim Ratios
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Imprimis Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Imprimis Pharmaceuticals Inc, Key Facts
Imprimis Pharmaceuticals Inc, Key Employees
Imprimis Pharmaceuticals Inc, Key Employee Biographies
Imprimis Pharmaceuticals Inc, Major Products and Services
Imprimis Pharmaceuticals Inc, History
Imprimis Pharmaceuticals Inc, Subsidiaries
Imprimis Pharmaceuticals Inc, Key Competitors
Imprimis Pharmaceuticals Inc, Ratios based on current share price
Imprimis Pharmaceuticals Inc, Annual Ratios
Imprimis Pharmaceuticals Inc, Annual Ratios (Cont.1)
Imprimis Pharmaceuticals Inc, Interim Ratios
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Imprimis Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Imprimis Pharmaceuticals Inc, Performance Chart (2013 - 2017)
Imprimis Pharmaceuticals Inc, Ratio Charts
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
COMPANIES MENTIONED
Trevena Inc
Omeros Corp
Johnson & Johnson
InSite Vision Inc
Bausch & Lomb Inc
Abbott Medical Optics Inc
Imprimis Pharmaceuticals Inc, Performance Chart (2013 - 2017)
Imprimis Pharmaceuticals Inc, Ratio Charts
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
COMPANIES MENTIONED
Trevena Inc
Omeros Corp
Johnson & Johnson
InSite Vision Inc
Bausch & Lomb Inc
Abbott Medical Optics Inc